妊娠期1型糖尿病的闭环胰岛素输注:CIRCUIT随机临床试验
CIRCUIT为开放标签随机试验,在加拿大和澳大利亚14个中心纳入妊娠14周前、1型糖尿病孕妇,1:1随机至闭环胰岛素输注组(n=46)或标准治疗组(胰岛素泵或每日多次注射,n=45),均使用持续葡萄糖监测。主要终点为妊娠16至34周妊娠特异性血糖范围(63-140 mg/dL)时间百分比:闭环组65.4% vs 标准治疗组50.3%,校正后平均差异12.5个百分点(95%CI 9.5-15.6),P<.001。闭环组严重低血糖1例,糖尿病酮症酸中毒闭环组2例、标准治疗组1例。结论支持该闭环系统用于妊娠期1型糖尿病。
要点
- 妊娠16-34周妊娠特异性血糖范围(63-140 mg/dL)时间百分比:闭环组65.4% vs 标准治疗组50.3%,校正后平均差异12.5个百分点(95%CI 9.5-15.6),P<.001。
- 研究纳入妊娠14周前、1型糖尿病孕妇,随机至闭环胰岛素输注(n=46)或标准治疗(胰岛素泵或每日多次注射,n=45),均使用持续葡萄糖监测。
- 安全性:闭环组严重低血糖1例;糖尿病酮症酸中毒闭环组2例、标准治疗组1例。
- 主要分析纳入88例,随机91例,入组94例中3例随机前妊娠丢失。
- 作者结论:这些发现支持该闭环系统用于妊娠期1型糖尿病孕妇。
适用人群与场景
- 妊娠14周前、1型糖尿病孕妇,在加拿大和澳大利亚14个临床中心入组,随访至产后6周。
- 随机分组91例,主要分析纳入88例。
处置流程与药物剂量
- 闭环胰岛素输注组(n=46)使用闭环系统。
- 标准治疗组(n=45)使用胰岛素泵或每日多次胰岛素注射。
- 两组均使用持续葡萄糖监测。
研究设计与关键结果
- 开放标签随机试验,14个中心,入组94例,随机91例(闭环组46例、标准治疗组45例),主要分析88例;平均年龄31.7岁(SD 5.2),早孕期血红蛋白A1c 7.4%(SD 1.0%)。
- 主要终点妊娠16-34周妊娠特异性血糖范围(63-140 mg/dL)时间百分比:闭环组65.4% vs 标准治疗组50.3%,校正后平均差异12.5个百分点(95%CI 9.5-15.6),P<.001。
- 严重低血糖:闭环组1例;糖尿病酮症酸中毒:闭环组2例、标准治疗组1例。
证据类型、等级与局限
- 证据类型:开放标签随机临床试验(CIRCUIT)。
- 试验注册号:ClinicalTrials.gov NCT04902378。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现支持该闭环系统用于妊娠期1型糖尿病孕妇。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Hyperglycemia-related pregnancy complications occur in 50% of pregnant women with type 1 diabetes. Closed-loop insulin systems improve glycemia outside of pregnancy but have had limited testing in pregnancy.
OBJECTIVE: To assess the efficacy of a closed-loop system in pregnancy.
DESIGN, SETTING, AND PARTICIPANTS: Open-label trial enrolling pregnant women with type 1 diabetes at 14 clinical centers in Canada and Australia before 14 weeks' gestation with follow-up until 6 weeks postpartum. Enrollment occurred between June 2021 and July 2024 and follow-up was completed in March 2025.
INTERVENTIONS: Participants were randomized 1:1 to closed-loop therapy (n = 46) or standard care (insulin pump or multiple daily insulin injections) (n = 45) with continuous glucose monitoring.
MAIN OUTCOMES AND MEASURES: The primary outcome was the percentage of time spent in the pregnancy-specific glucose range (63-140 mg/dL), measured by continuous glucose monitoring from 16 to 34 weeks' gestation.
RESULTS: Among 94 enrolled participants, 3 experienced pregnancy loss prior to randomization, 91 were randomized (mean age, 31.7 [SD, 5.2] years; early pregnancy hemoglobin A1c, 7.4% [SD, 1.0%]), and 88 were included in the primary analysis. The mean percentage of time spent in the pregnancy-specific glucose range from 16 to 34 weeks' gestation was 65.4% in the closed-loop group and 50.3% in the standard care group (mean adjusted difference, 12.5 [95% CI, 9.5-15.6] percentage points; P < .001). There was 1 episode of severe hypoglycemia in the closed-loop group, and there were 2 episodes of diabetic ketoacidosis in the closed-loop group and 1 in the standard care group.
CONCLUSION AND RELEVANCE: Pregnant women with type 1 diabetes using a closed-loop system spent significantly more time in the pregnancy-specific glucose range than those receiving standard care. These findings support the use of this closed-loop system in pregnant women with type 1 diabetes.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04902378.
参考来源
- Donovan LE, Lemieux P, Dunlop AD, et al. Closed-Loop Insulin Delivery in Type 1 Diabetes in Pregnancy: The CIRCUIT Randomized Clinical Trial. JAMA. 2025. PMID: 41134589. doi:10.1001/jama.2025.19578
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。